… in diagnosing neurodegenerative diseases is their heterogeneity. Clinical symptoms are … ,
huge progress has been made in the field of biomarkers for neurodegenerative diseases. The …

… In this review, only ncRNAs will be discussed because they are more likely to have a
clinical utility in neurodegenerative disease. Among ncRNAs, miRNAs are certainly the most …

… , proteostasis impairment, mitochondrial dysfunction, and other neurodegenerative events,
occur in onset or during the progression of neurodegenerative diseases [3,4]. In this regard, …

… of underlying mutations in neurodegenerative diseases is of … disease, epilepsy, and MS.
Finally, we discuss the NGS challenges and opportunities in neurodegenerative diseases…

… ROS in various neurodegenerative diseases may be critical … damage in major
neurodegenerative diseases including AD, PD, … in the field of neurodegenerative diseases. …

… In neurodegenerative disease, the final diagnosis is usually obtained by … of neurodegenerative
processes (Alzheimer’s disease, Parkinson’s disease, etc.) does not exist in a clinical …

… during Neurodegenerative Disease For all neurodegenerative diseases mentioned in this
review, the incidence of neuronal apoptosis during the course of disease has been shown by …

… an exhaustive discussion of the scientific opportunities of PET/MR imaging with regard to
neurodegeneration is beyond the scope of this article, which is focused on clinical applications. …

… the gene therapy clinical applications that have been conducted for neurodegenerative
diseases. … that should allow new clinical applications with high beneficial potential are discussed. …

… protection or treatment of neurodegenerative diseases, since the … the symptoms of
neurodegenerative diseases, there are many … of the major neurodegenerative diseases in …